Podium Abstract
Eposter Presentation
 
Accept format: PDF. The file size should not be more than 5MB
 
Accept format: PNG/JPG/WEBP. The file size should not be more than 2MB
 
Submitted
Abstract
Comprehensive Bioinformatics Approach for Identifying Lipid-Related Markers in Bladder Cancer Prognosis
Podium Abstract
Basic Research
Novel Advances: Other Urology Translational Studies
Author's Information
8
No more than 10 authors can be listed (as per the Good Publication Practice (GPP) Guidelines).
Please ensure the authors are listed in the right order.
Taiwan
Yu-De Wang thomas1101111@gmail.com China medical university hospital urology Taichung City Taiwan *
Chi-Ping Huang huangchiping@yahoo.com.tw China medical university hospital urology Taichung City Taiwan -
Chia-Hsin Liu b881642@gmail.com China medical university graduate institute of biomedical sciences, school of medicine, college of medicine Taichung City Taiwan -
Pei-Chun Shen y800418@gmail.com China medical university graduate institute of biomedical sciences, school of medicine, college of medicine Taichung City Taiwan -
Hsiu-Cheng Liu hcliu0307@gmail.com China medical university graduate institute of biomedical sciences, school of medicine, college of medicine Taichung City Taiwan -
Meng-Hsin Tsai tiff130820@gmail.com China medical university graduate institute of biomedical sciences, school of medicine, college of medicine Taichung City Taiwan -
Yo-Liang Lai yolianglai@gmail.com China medical university hospital Radiology Taichung City Taiwan -
Wei-Chung Cheng cwc0702@gmail.com China medical university graduate institute of biomedical sciences, school of medicine, college of medicine Taichung City Taiwan -
 
 
 
 
 
 
 
 
 
 
 
 
Abstract Content
Bladder cancer (BLCA) remains a pressing global health challenge, characterized by high recurrence, progression, and mortality rates. Traditional prognostic tools, such as the TNM classification, show limited accuracy, particularly in the context of immune checkpoint inhibitors (ICI). In this study, we employed comprehensive bioinformatics analyses on the TCGA dataset to identify genes that are differentially expressed and methylated in BLCA.
We analyzed transcriptomic and methylation data from the TCGA BLCA cohort to identify differentially expressed and differentially methylated genes. By integrating both datasets, and using machine learning techniques were employed to generate a 25-gene survival signature, which was validated using independent cohorts, including the IMvigor 210 trial. Functional enrichment and KEGG pathway analyses were performed to elucidate the biological roles of the signature, and in vitro experiments confirmed the involvement of key lipid metabolism genes.
Our analysis identified a 25-gene signature significantly associated with 5-years disease-specific survival (DSS) in BLCA patients(HR:2.3, p<0.001). Functional enrichment analysis highlighted key genes like FASN, SCD within this signature, emphasizing the critical involvement of lipid metabolism pathways, particularly those related to FASN and SCD. The prognostic value of this gene signature was validated across four independent cohorts, including the IMvigor 210 clinical trial dataset, consistently distinguishing high-risk from low-risk patients and correlating with survival outcomes across BLCA stages. In vitro experiments further demonstrated that inhibiting FASN and SCD impairs BLCA cell proliferation and migration, suggesting their potential as therapeutic targets.
This study introduces a novel biomarker for BLCA prognosis while shedding light on its underlying molecular mechanisms. The findings underscore the importance of this biomarker in the clinical epigenetics of BLCA and offer new avenues for personalized treatment strategies
Urothelial Cancer, Novel Biomarkers, lipid
 
 
 
 
 
 
 
 
 
 
1774
 
Presentation Details
Free Paper Podium(03): Oncology Bladder UTUC (A)
Aug. 14 (Thu.)
16:42 - 16:48
13